Active substance
Results for the substance axicabtagen ciloleucel
1 result
About this active substance
Axicabtagene ciloleucel is a CAR-T cell therapy (chimeric antigen receptor T-cell therapy) used in the treatment of relapsed or refractory large B-cell lymphoma and other aggressive lymphomas. This therapy involves collecting the patient's T-cells, genetically modifying them to express a specific receptor that recognizes the CD19 protein on tumor cells, and reinfusing them into the body.
Axicabtagene ciloleucel is administered as a single intravenous infusion following a lymphodepleting chemotherapy regimen. The treatment aims to destroy tumor cells by activating and proliferating the modified T-cells.
Common side effects include cytokine release syndrome (CRS), neurotoxicity, fever, hypotension, and infections. These reactions can be severe and require careful monitoring and prompt management.
Axicabtagene ciloleucel represents a major innovation in hematologic cancer treatment, offering patients with aggressive lymphomas a personalized and effective therapeutic option with curative potential.
Axicabtagene ciloleucel is administered as a single intravenous infusion following a lymphodepleting chemotherapy regimen. The treatment aims to destroy tumor cells by activating and proliferating the modified T-cells.
Common side effects include cytokine release syndrome (CRS), neurotoxicity, fever, hypotension, and infections. These reactions can be severe and require careful monitoring and prompt management.
Axicabtagene ciloleucel represents a major innovation in hematologic cancer treatment, offering patients with aggressive lymphomas a personalized and effective therapeutic option with curative potential.